Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gustafsson

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Thrombosis and Haemostasis|February 23, 2002
Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjectsTroy C Sarich, Ulf G Eriksson, Christer Mattsson, et al.
Bioorganic & Medicinal Chemistry Letters|August 14, 2009
From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifsStephen Hanessian, Eric Therrien, Jianbin Zhang, et al.
Journal of Medicinal Chemistry|June 28, 2016
Macrocyclic Prodrugs of a Selective Nonpeptidic Direct Thrombin Inhibitor Display High Permeability, Efficient Bioconversion but Low BioavailabilityVincent Andersson, Fredrik Bergström, Jonas Brånalt, et al.
Thrombosis and Haemostasis|February 23, 2002
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgeryBengt I Eriksson, Ann-Christin Arfwidsson, Lars Frison, et al.
Scientific Reports|June 18, 2014
Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivoMarianne Månsson, Inge Kalies, Göran Bergström, et al.
Thrombosis Research|July 9, 2013
A serendipitously identified novel small molecule procoagulant compound giving rise to a high-throughput screening assay based on human plasmaDavid Gustafsson, Sofi Nielsen, Jane McPheat, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 14, 2003
Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humansUlf G Eriksson, Ulf Bredberg, Kurt-Jürgen Hoffmann, et al.
Journal of the American College of Cardiology|February 25, 2003
Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjectsTroy C Sarich, Michael Wolzt, Ulf G Eriksson, et al.
Clinical Pharmacokinetics|July 8, 2003
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysisUlf G Eriksson, Jaap W Mandema, Mats O Karlsson, et al.
Lancet (London, England)|November 16, 2002
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trialBengt I Eriksson, David Bergqvist, Peter Kälebo, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Thrombosis and Haemostasis|February 23, 2002
Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjectsTroy C Sarich, Ulf G Eriksson, Christer Mattsson, et al.
Bioorganic & Medicinal Chemistry Letters|August 14, 2009
From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifsStephen Hanessian, Eric Therrien, Jianbin Zhang, et al.
Journal of Medicinal Chemistry|June 28, 2016
Macrocyclic Prodrugs of a Selective Nonpeptidic Direct Thrombin Inhibitor Display High Permeability, Efficient Bioconversion but Low BioavailabilityVincent Andersson, Fredrik Bergström, Jonas Brånalt, et al.
Thrombosis and Haemostasis|February 23, 2002
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgeryBengt I Eriksson, Ann-Christin Arfwidsson, Lars Frison, et al.
Scientific Reports|June 18, 2014
Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivoMarianne Månsson, Inge Kalies, Göran Bergström, et al.
Thrombosis Research|July 9, 2013
A serendipitously identified novel small molecule procoagulant compound giving rise to a high-throughput screening assay based on human plasmaDavid Gustafsson, Sofi Nielsen, Jane McPheat, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 14, 2003
Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humansUlf G Eriksson, Ulf Bredberg, Kurt-Jürgen Hoffmann, et al.
Journal of the American College of Cardiology|February 25, 2003
Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjectsTroy C Sarich, Michael Wolzt, Ulf G Eriksson, et al.
Clinical Pharmacokinetics|July 8, 2003
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysisUlf G Eriksson, Jaap W Mandema, Mats O Karlsson, et al.
Lancet (London, England)|November 16, 2002
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trialBengt I Eriksson, David Bergqvist, Peter Kälebo, et al.
Pageof 4